Predicted Top 5 Worldwide Selling Drugs in 2025: A Market Update
Keytruda ($30B sales), Ozempic, Mounjaro, Dupixent, and Skyrizi dominate 2025's pharma market, targeting oncology, diabetes/obesity, and immunology with breakthrough biologics and multi-indication strategies.
June 23, 2025
by David Orchard-Webb
Summary of Immune Checkpoint Inhibitor Combined with ADC
With the maturity of ADC technology, the combined scheme of IO and ADC is showing a therapeutic potential.
July 25, 2023
by Yefenghong/PharmaSources
Early research suggests Merck cancer drug may target dormant HIV
Antiretroviral treatments now allow many HIV patients to lead normal lives, but the drugs do not completely remove the virus from the body
January 29, 2022
by ExpressPharma
Merck’s Keytruda obtains EC approval as adjuvant therapy for kidney cancer
In a Phase III trial, Keytruda lowered the disease recurrence or mortality risk by 32% versus placebo.
January 28, 2022
by Pharmaceutical-Technology
Everest Medicines Will Participate in a Clinical Trial with Gilead and MSD to Evaluate Trodelvy® in Combination with KEYTRUDA® (pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), today announced it will participate in a study pursuant to a clinical trial collaboration between Gilead and MSD...
January 11, 2022
by prnasia
NICE recommends MSD’s Keytruda in combination with chemotherapy for routine treatment of lung cancer
With over 48,000 new cases diagnosed per year, lung cancer is the third most common cancer in the UK.
January 7, 2022
by pharmatimes
FDA grants Fast Track status to Genprex’s drug for NSCLC treatment
In preclinical studies, Reqorsa plus Keytruda were found to be efficient versus Keytruda alone in boosting survival.
January 5, 2022
by Pharmaceutical-Technology
Japan approves Keytruda plus Lenvima combination for endometrial cancer treatment
the Ministry of Health, Labour and Welfare (MHLW) of Japan has approved Keytruda plus Lenvima combination to treat endometrial carcinoma.
December 28, 2021
by drugs
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® as Adjuvant Therapy for Renal Cell Carcinoma
Merck announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA...
December 20, 2021
by AmericanPharmaceuticalReview
SOTIO Announces Clinical Collaboration with MSD to Evaluate IL-15 Superagonist, SOT101, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it has entered into a clinical trial collaboration and supply agreement with MSD...
December 9, 2021
by B3Cnewswire
FDA Approves Merck’s KEYTRUDA® as Adjuvant Treatment for Patients with Stage IIB or IIC Melanoma
Merck announced that the FDA has approved KEYTRUDA, Merck’s anti-PD-1 therapy, for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection.
December 7, 2021
by AmericanPharmaceuticalReview
Merck’s Keytruda obtains FDA approval as adjuvant therapy for melanoma patients
Merck’s anti-PD-1 therapy, Keytruda, has obtained approval from the US Food and Drug Administration (FDA) as an adjuvant therapy for stage IIB or IIC melanoma patients aged 12 years and above.
December 7, 2021
by Pharmaceutical-Business-Review